MedTrace Logo

Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19

NCT04928495 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2021-06-30

No results posted yet for this study

Summary

Clinical, control, double-blind, randomized experimentation with N-acetylcysteine and bromhexine for COVID-19.

Conditions

Interventions

DRUG

Vitamin C

Vitamin C 500 mg / day for ten days

DRUG

N-acetylcysteine (NAC)

N-acetylcysteine 1800 mg / day for ten days.

DRUG

NAC + Bromhexine (BMX)

NAC + Bromhexine (BMX) 32 mg / day for ten days.

Sponsors & Collaborators

  • Paulista School of Medicine-EPM, UNIFESP

    collaborator UNKNOWN

  • Health Surveillance Secretariat - SVS

    collaborator UNKNOWN

  • Central Laboratory of Public Health of Ceara - LACEN-CE

    collaborator UNKNOWN

  • Leonardo da Vinci Hospital - HLV

    collaborator UNKNOWN

  • São José Hospital for Infectious Diseases - HSJ

    collaborator UNKNOWN

  • Ceará Health Secretariat - SESA

    collaborator UNKNOWN

  • Municipal Health Secretary - SMS-Fortaleza

    collaborator UNKNOWN

  • Universidade Federal do Ceara

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-15
Primary Completion
2022-04-09
Completion
2022-06-09

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04928495 on ClinicalTrials.gov